Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567030 | 1.00 | ALDH1A1 (0.36) | ALDH1A1PKMLMNATSHRSRD5A1 | |
| SCHEMBL6638258 | 1.00 | ALDH1A1 (0.36) | ALDH1A1PKMLMNATSHRSRD5A1 | |
| SCHEMBL8465326 | 1.00 | ALDH1A1 (0.36) | ALDH1A1PKMLMNATSHRSRD5A1 | |
| SCHEMBL9733418 | 0.98 | MAPT (0.35) | ALDH1A1PKMLMNATSHRSRD5A1 | |
| SCHEMBL9733421 | 0.98 | MAPT (0.35) | ALDH1A1PKMLMNATSHRSRD5A1 | |
| SCHEMBL9359669 | 0.95 | SRD5A1 (0.33) | ALDH1A1PKMLMNATSHRSRD5A1 | |
| SCHEMBL6675762 | 0.95 | SRD5A1 (0.33) | ALDH1A1PKMLMNATSHRSRD5A1 | |
| SCHEMBL26673240 | 0.93 | SRD5A1 (0.38) | ALDH1A1PKMLMNATSHRSRD5A1 | |
| SCHEMBL18150856 | 0.91 | SRD5A1 (0.37) | ALDH1A1PKMLMNATSHRSRD5A1 | |
| SCHEMBL17338063 | 0.91 | ALDH1A1 (0.36) | ALDH1A1PKMLMNATSHRSRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5338861-A | Cleaving lactam N-carboxylate or lactim O-carboxylate with elimination of carbon dioxide by heating in gas or liquid phase | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | claimed |
| CN-118324695-A | Method for selectively preparing quinoline-2-ketone or 3, 4-dihydro-quinoline-2-ketone compound under regulation of photocatalyst | 浙江工业大学 | 2024-07-12 | — | — | CN | disclosed |
| WO-2022237849-A1 | NMDA RECEPTOR ANTAGONIST AND USE THEREOF | 中国科学院上海有机化学研究所 | 2022-11-17 | — | — | WO | disclosed |
| US-9758788-B2 | Mutagenesis of plants for overproduction of selective estrogen receptor modulators | Naprogenix, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9630935-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2017-04-25 | — | — | US | disclosed |
| US-20160280671-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2016-09-29 | — | — | US | disclosed |
| US-20160040176-A1 | TARGET-DIRECTED BIOSYNTHESIS OF PLANT METABOLITES | Naprogenix, Inc. | 2016-02-11 | — | — | US | disclosed |
| EP-1692157-B1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMA (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8242150-B2 | Triazole derivatives for treating alzheimer'S disease and related conditions | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2468744-A2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-0170775-B1 | DERIVATIVES OF BICYCLIC AMINO ACIDS, PROCESSES FOR THEIR PREPARATION, AGENTS CONTAINING THEM AND THEIR USE AS WELL AS BICYCLIC AMINO ACIDS AS INTERMEDIATES AND PROCESS FOR THEIR PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-11-08 | — | — | EP | disclosed |
| US-4778894-A | TRANS-OCTAHYDROPYRAZOLOQUINOLINES; INTERMEDIATES FOR HYPOTENSIVE AGENTS | ELI LILLY AND COMPANY (US) | 1988-10-18 | — | — | US | disclosed |
| US-4778894-A | TRANS-OCTAHYDROPYRAZOLOQUINOLINES; INTERMEDIATES FOR HYPOTENSIVE AGENTS | ELI LILLY AND COMPANY (US) | 1988-10-18 | — | — | US | disclosed |
| US-4719203-A | CALCIUM METABOLISM DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1988-01-12 | — | — | US | disclosed |
| US-4596871-A | Tautomeric mixtures | ELI LILLY AND COMPANY (US) | 1986-06-24 | — | — | US | disclosed |
| EP-0170775-A1 | Derivatives of bicyclic amino acids, processes for their preparation, agents containing them and their use as well as bicyclic amino acids as intermediates and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-02-12 | — | — | EP | disclosed |
| EP-0145121-A2 | Pyrazoloquinolines, process for their preparation, and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1985-06-19 | — | — | EP | disclosed |
| EP-0112604-A1 | Novel resolved keto compounds and process | ELI LILLY AND COMPANY (US) | 1984-07-04 | — | — | EP | disclosed |
| EP-0084164-A2 | Derivatives of bicyclic amino acids, process for their preparation, agents containing them and their use, as well as bicyclic amino acids as intermediates, and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-07-27 | — | — | EP | disclosed |
| US-3972890-A | ACID CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280671-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | TGFB1, REN, TGFB2 | ALDH1A1 1172/4885PKM 2438/4885LMNA 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.